
    
      Patients will be recruited for 1 year and be follow-up for 3 years. Patients will make active
      hospital visit for collection of blood samples, which will be analyzed to develop a
      biosignature at the end of the study to detect very early hepatocellular carcinoma and
      stratify risk population for intensive follow-up.
    
  